Pembrolizumab plus olaparib improves PFS in BRCA-non-mutated ovarian cancer

This phase 3 trial (KEYLYNK-001) tested pembrolizumab plus chemotherapy followed by pembrolizumab-olaparib maintenance versus chemotherapy alone as first-line treatment for advanced BRCA1/2 non-mutated epithelial ovarian, primary peritoneal, or fallopian tube cancer. The trial reported that pembrolizumab-olaparib significantly improved progression-free survival versus control at both interim and final analysis, in both the PD-L1 CPS 10 or higher and intention-to-treat populations, while pembrolizumab alone did not significantly improve progression-free survival versus control. The trial also reported higher rates of grade 3 or higher treatment-related adverse events and serious adverse events, including treatment-related deaths, in the pembrolizumab-olaparib and pembrolizumab groups compared with control.

Most relevant for: Patients with newly diagnosed stage III-IV BRCA non-mutated epithelial ovarian, primary peritoneal, or fallopian tube cancer being considered for first-line treatment.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.